Business Context and Reporting Period
This Form 8-K Current Report was filed by LifeStance Health Group, Inc. on September 9, 2026, with the report signed on September 11, 2026. The filing discloses an "Other Event" (Item 8.01) regarding a secondary offering of the Company's common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten secondary offering of 22,250,000 shares of Common Stock.
- Proceeds to Company: $0. The filing explicitly states the Company did not receive any proceeds from the offering as all shares were sold by Selling Stockholders.
- Company Repurchase: The Company agreed to purchase 2,000,000 of the shares sold by the Selling Stockholders from the Underwriter at the same price paid by the Underwriter.
- Underwriter Compensation: The Underwriter (Barclays Capital Inc.) received no compensation for the shares repurchased by the Company.
- Closing Date: September 11, 2026.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a disclosure of a corporate event, not a financial results report.
Material Changes
The filing does not report material changes to the Company's operating results, financial position, or liquidity compared to prior periods. The primary change is the dilution of existing shareholders due to the issuance of 22,250,000 shares by Selling Stockholders, offset partially by the Company's repurchase of 2,000,000 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the Company's operations. The transaction was conducted pursuant to a registration statement on Form S-3 filed on May 21, 2024. Legal counsel (Ropes & Gray LLP) provided an opinion on the validity of the shares sold.
Investor Verification Checklist
- Verify the identity of the "Selling Stockholders" listed in Schedule II of the Underwriting Agreement to understand the source of the shares.
- Confirm the final share count and dilution impact after the Company's repurchase of 2,000,000 shares.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific pricing details and lock-up provisions.
- Note that the Company received no capital from this transaction; investors should look to recent 10-Q or 10-K filings for actual financial performance data.